Skip to content
Clinical Trials – home
Not recruiting

Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on patients with metastatic colorectal cancer who have specific genetic characteristics - namely RAS and B-RAF wild-type mutations, which are determined through a blood test analyzing circulating cell-free DNA. The study compares two different combination treatments: FOLFIRINOX plus panitumumab versus mFOLFOX6 plus panitumumab.

The treatment combinations include several medications given through infusion or injection. The first combination consists of oxaliplatin, irinotecan, fluorouracil, folinic acid (or calcium levofolinate), and panitumumab. The second combination includes some of the same medications but without irinotecan. These medications are types of chemotherapy drugs, with panitumumab being a targeted therapy that specifically fights cancer cells.

The main purpose of this study is to evaluate how well patients respond to these treatment combinations, specifically looking at whether the cancer completely disappears after treatment. The study will monitor patients' responses through regular medical imaging and blood tests to track the effectiveness of the treatments. Patients will receive up to 12 rounds of treatment, with regular check-ups to monitor their health and the cancer's response to therapy.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment assignment

    You will be randomly assigned to one of two treatment groups for metastatic colorectal cancer

    Your treatment will be based on the results of a blood test that checks for specific genetic markers (RAS and B-RAF)

  2. Step 2

    Treatment administration - Group 1

    If assigned to group 1, you will receive FOLFIRINOX plus panitumumab

    The treatment includes infusions of: oxaliplatin, irinotecan, panitumumab, folinic acid, and fluorouracil

    Treatments will be given in cycles for up to 12 cycles total

  3. Step 3

    Treatment administration - Group 2

    If assigned to group 2, you will receive mFOLFOX6 plus panitumumab

    The treatment includes infusions of: oxaliplatin, panitumumab, folinic acid, and fluorouracil

    Treatments will be given in cycles for up to 12 cycles total

  4. Step 3

    Monitoring during treatment

    Regular medical examinations will check your response to treatment

    Imaging scans (CT or MRI) will be performed to measure tumor response

    Blood tests will monitor your health status

    Side effects will be monitored and recorded throughout treatment

  5. Step 4

    Response evaluation

    Your response to treatment will be evaluated after 4 cycles to measure early tumor changes

    Complete response will be confirmed by additional scans 4 to 6 weeks after treatment completion

    If your cancer becomes operable during treatment, surgery may be considered

  6. Step 5

    Follow-up period

    After completing treatment, regular follow-up visits will continue

    Your health status will be monitored until 2028

    Long-term effects and survival will be tracked throughout the follow-up period

Who can join the trial?

16 criteria

  • Age must be between 18 and 75 years
  • Must have active social security coverage
  • Must provide informed consent by signing the written consent form
  • Blood uracil levels must be less than 16 ng/ml
  • Must have good physical performance status (ECOG score of 0 or 1, meaning able to perform daily activities with minimal limitations)
  • Must have confirmed colon or rectal cancer through tissue examination (adenocarcinoma)
  • Must have metastatic disease (cancer that has spread) that cannot be removed by surgery
  • Must have specific genetic characteristics: normal (wild-type) versions of genes called K-Ras, N-Ras, and B-Raf, as determined by blood testing
  • Must have cancer that can be measured using standard imaging methods
  • Must have adequate blood test results including:
    • White blood cell count above 2,000/mm³
    • Hemoglobin above 9 g/dL
    • Platelet count above 100,000/mm³
    • Liver function tests within specified limits
    • Kidney function showing clearance above 50 mL/min
    • Must have life expectancy of at least 3 months
    • Must use appropriate birth control if applicable

Who cannot join the trial?

15 criteria

  • Prior treatment with FOLFIRINOX chemotherapy or panitumumab therapy
  • Known mutations in RAS or B-RAF genes confirmed by blood test
  • Active brain metastases (cancer spread to the brain)
  • History of other cancers within the past 5 years, except for successfully treated non-melanoma skin cancer or cervical cancer in situ
  • Severe heart conditions including heart failure, unstable angina, or heart attack within 6 months
  • Uncontrolled high blood pressure
  • Serious infections requiring antibiotics
  • Major surgery within 4 weeks before starting the study
  • Pregnant or breastfeeding women
  • Known allergic reactions to study medications
  • Severe kidney or liver dysfunction
  • Current participation in other clinical trials
  • Any condition that could interfere with study procedures or patient safety
  • Unable to provide informed consent
  • Mental conditions that prevent understanding of study requirements
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Panitumumab

    is a targeted therapy medication that works by blocking a specific protein called EGFR on cancer cells. It's used to treat colorectal cancer by helping to stop cancer cells from growing and spreading.

  • FOLFIRINOX

    is a combination chemotherapy treatment that includes three different cancer-fighting drugs: fluorouracil, irinotecan, and oxaliplatin. This combination works together to kill cancer cells and prevent them from multiplying.

  • mFOLFOX6

    is a modified combination chemotherapy treatment that includes fluorouracil, leucovorin, and oxaliplatin. This combination is commonly used to treat colorectal cancer by attacking cancer cells in different ways to stop their growth and spread.

What is already known about the treatment

  • Panitumumab

    A targeted biological therapy administered through intravenous infusion that is used in the treatment of metastatic colorectal cancer, specifically in patients with wild-type RAS and B-RAF genes. This monoclonal antibody works by targeting and blocking the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from receiving growth signals and thus inhibiting tumor growth. As a first-line treatment option, it is often combined with chemotherapy regimens such as FOLFIRINOX or FOLFOX to enhance treatment effectiveness in selected patients.

  • FOLFIRINOX

    A combination chemotherapy regimen administered intravenously that consists of four drugs: fluorouracil, leucovorin, irinotecan, and oxaliplatin. This intensive treatment protocol is used in the management of metastatic colorectal cancer and works through multiple mechanisms to prevent cancer cell division and growth. The combination demonstrates enhanced effectiveness compared to single-agent treatments, though it may have more side effects than simpler chemotherapy regimens.

  • FOLFOX

    A chemotherapy combination administered intravenously that includes fluorouracil, leucovorin, and oxaliplatin (specifically mFOLFOX6 in this context). This widely-used treatment protocol for metastatic colorectal cancer works by interfering with cancer cell DNA replication and division processes. The treatment is typically given in cycles and represents a standard care option that balances effectiveness with manageable side effects.

Investigated diseases

Metastatic Colorectal Cancer - A condition where cancer that begins in the colon or rectum spreads to other parts of the body. It develops from abnormal cells in the inner lining of the colon or rectum that grow and multiply uncontrollably. The cancer cells can break away from the original tumor and travel through the bloodstream or lymphatic system to form new tumors in other organs, most commonly the liver and lungs. In RAS and B-RAF wild-type cases, the cancer cells have normal (non-mutated) versions of these specific genes, which can influence how the disease develops and responds to treatment. This type of colorectal cancer typically begins as small growths called polyps that develop into cancerous tumors over time.
Trial detailsLast updated 30 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-510645-34-00Protocol codeUC-0110/1608Estimated enrolment225 patientsSponsorUnicancer

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.